Illuminating early breast cancer treatment with genomic testing

MammaPrint® + BluePrint® provide results in just 6 days—going beyond clinical factors to reveal recurrence risk and tumor biology to personalize treatment decisions.*†

Agendia MammaPrint breast cancer recurrence test
 

Learn the likelihood of a patient’s breast cancer recurring.


Agendia BluePrint breast cancer genomic subtyping test
 

Determine the underlying genomics driving the growth of a tumor.


Built on science. Proven in practice.

Strong evidence. Real impact.

Decades of research and real-world data support better breast cancer treatment options and outcomes.

View Clinical Evidence
  • 180+

    Publications & abstracts

  • 23,000+

    Patients enrolled in the FLEX Study

  • 45+

    Countries using Agendia tests

  • 7

    Guidelines recognized

FOR BETTER OUTCOMES

A more complete understanding of each patient’s breast cancer.

Agendia’s genomic testing platforms help you match each patient to the right treatment at the right time to help minimize under- and over-treatment.

African American breast cancer patient
FOR PROVEN RESULTS

Trusted by leading physicians and institutions around the world

Cancer studies

Landmark Studies

Data on the validation and utility of MammaPrint and BluePrint for patients with early stage breast cancer.

Women reading book

Latest News

The most recent data and news from Agendia to keep you up-to-date on how our tests can support you and your patients.

Breast vancer patient news - "I am Here" - Agendia

Patient News

Agendia and artist Andrea Caceres go “beyond the mammogram” in a portrait series illustrating people touched by breast cancer.

NEWS

Press Releases

* Based on findings from clinical studies. Results should be taken in the context of other relevant clinico-pathological factors and standard practice of medicine.

† McKelley, et al. SABCS 2020. Agendia is committed to delivering results in less than 10 business days, and results are provided within 6 business days for the majority of cases.

Are you a breast cancer patient?

Learn more about how genomic testing can improve your path to recovery.

Breast cancer patient advocacy
Breast cancer patient advocacy

Are you a breast cancer patient?

Learn more about how genomic testing can improve your path to recovery.


MammaPrint®
BluePrint®

Ready to take the next step?

Order MammaPrint® + BluePrint® genomic tests to assess recurrence risk and tumor biology and help guide early-stage breast cancer treatment decisions.

Order a Test Learn More